Mode
Text Size
Log in / Sign up
Phase 3 N=516 Treatment

Reverse Shoulder Prosthesis Study

Rotator Cuff Arthropathy · Failed Total Shoulder · Failed Hemi-arthroplasty

Enrolled (actual)
516
Serious AEs
0.0%
Results posted
Apr 2011
Primary outcome: Primary: American Shoulder and Elbow Surgeons Shoulder Score — 76; 62; 77 Units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Reverse Shoulder Prosthesis (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Encore Medical, L.P.
Primary completion
Jun 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
American Shoulder and Elbow Surgeons Shoulder Score
76; 62; 77
PRIMARY
Average Range of Motion
119.6; 84.4; 120.4; 33.3; 23.3; 37.1
PRIMARY
Subject Satisfaction With Surgery
31; 20; 60; 18; 12; 27
PRIMARY
Have Surgery Again?
52; 40; 88; 7; 9; 10
PRIMARY
Neer's "Limited Goals"
33; 9; 59; 26; 40; 39
PRIMARY
Radiographic Failures
0; 0; 0
PRIMARY
Safety Assessment
12; 23; 14; 27; 25; 14

Summary

The objective of this clinical study is to evaluate the safety and efficacy of the Encore Reverse Shoulder Prosthesis (RSP). The clinical results of the RSP will be compared to clinical results published in literature for rotator cuff arthropathy and salvage procedures.

Eligibility Criteria

Inclusion Criteria

  • Irreparable rotator cuff or failed hemi or total shoulder arthroplasty with irreparable rotator cuff
  • Evidence of upward displacement of the humeral head with respect to the glenoid
  • Loss of glenohumeral joint space
  • Functional deltoid muscle
  • Patient is likely to be available for evaluation for the duration of the study
  • Visual Analog Pain Scale 5 or greater

Exclusion Criteria

  • Non functional deltoid muscle
  • Active sepsis
  • Excessive glenoid bone loss
  • Pregnancy
  • Neurological abnormalities, which could hinder patient's ability or willingness to follow study procedures. For example, any that may restrict physical activities such as Parkinson's, Multiple Sclerosis, or previous stroke, which affects upper extremity.
  • Mental conditions that may interfere with ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the patient cannot understand the informed consent process, global dementia, prior strokes that interfere with the patient's cognitive abilities, senile dementia, and Alzheimer's Disease.
  • Prisoners
  • Conditions that place excessive demand on the implant (i.e. Charcot's joints, muscle deficiencies, refusal to modify postoperative physical activities, skeletal immaturity).
  • Known metal allergy (i.e., jewelry).
  • Visual Analog Pain Scale <5.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00764504). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search